Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report

BACKGROUND: Paclitaxel plus bevacizumab have shown a high response rate and prolonged progression-free survival in metastatic breast cancer patients. However, overall survival was not prolonged. Thus, no conclusion has been made on the effectiveness of bevacizumab. In our report, taxane plus bevaciz...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishizuna, Kazuo, Ninomiya, Jun, Kojima, Makoto, Kawashima, Miho, Nozaki, Miwako, Yamagishi, Hidetsugu, Ueda, Yoshihiko, Oya, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707777/
https://www.ncbi.nlm.nih.gov/pubmed/23830415
http://dx.doi.org/10.1186/1756-0500-6-254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707777/
https://www.ncbi.nlm.nih.gov/pubmed/23830415
http://dx.doi.org/10.1186/1756-0500-6-254

Ejemplares similares